A Phase 3 interventional study of Trifarotene 0.005 % Topical Cream and AKLIEF® in Acne Vulgaris, sponsored by Teva Pharmaceuticals USA. Completed at 14 sites in United States. Open to participants aged 12 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-26.
Sponsored by Teva Pharmaceuticals USA (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing trifarotene in Acne Vulgaris — none open to participants now, 1 under way, 1 of them phase 3. trifarotene · Acne Vulgaris.
Among the 12 studies testing trifarotene in Acne Vulgaris, this one is the 4th largest by enrollment, is the only one that started in 2022, is one of 6 in phase 3, and was the 9th registered.
791 studies on the registry are indexed under Acne Vulgaris; 94 are open to participants now.
Browse Acne Vulgaris studies →None of the 12 studies testing trifarotene in Acne Vulgaris is open now. The open studies under Acne Vulgaris, anywhere →
trifarotene: first FDA approval 2019 (AKLIEF). What it is approved for, and how studies give it, is on its page →
Of the 47 Acne Vulgaris studies recruiting now, 17 (36%) set no upper age limit and 29 (62%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.
This study: 12 Years to 40 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 1 started in 2022.
This study's enrollment of 807 is above the median of 70 across 673 interventional studies indexed under Acne Vulgaris.
Median enrollment 507 across the 12 interventional studies. Of the 11 that completed or were terminated, 9 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 12 have an industry lead sponsor. The 3 most frequent:
This study is registered under Teva Pharmaceuticals USA, one of the names counted as Teva Pharmaceutical Industries, Ltd.. Under that name alone:
Teva Pharmaceuticals USA is the lead sponsor of 176 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
Teva Pharmaceutical Industries, Ltd. has 9 studies filed under Acne Vulgaris — fewer than ten, so there is no comparison to draw.
1 of the studies testing trifarotene in Acne Vulgaris that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07186413Phase 3Galderma R&DA Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne Vulgaris | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing trifarotene in Acne Vulgaris, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To compare the safety and efficacy of the test (Trifarotene 0.005% cream), placebo (vehicle cream) and reference AKLIEF® (Trifarotene 0.005% cream) treatments to demonstrate clinical equivalence in subjects with acne vulgaris.
To compare the safety of Test, Reference, and Placebo treatments in patients with acne vulgaris. Subjects in this randomized, double-blind, three-arm, placebo controlled, parallel-design, multi-site study will be randomly assigned in a 1:1:1 ratio to treatment with the test product, reference product or placebo control, respectively.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects must have ≥ 25 non-inflammatory lesions (i.e., open and closed comedones) AND ≥ 20 inflammatory lesions (i.e., papules and pustules) AND ≤ 2 nodulocystic lesions (i.e.,nodules and cysts), at screening/baseline on the face.
(a) For the purposes of study treatment and evaluation, these lesions should be limited to the facial treatment area. All lesions will be counted, including those present on the nose. Subjects may have acne lesions on other areas of the body which will be excluded from the count and the Investigator's Global Assessment (IGA) evaluation (e.g., on the back, chest and arms).
Subjects must have a definite clinical diagnosis of acne vulgaris severity grade 2, 3, or 4 as per the Investigator's Global Assessment (IGA) (per Table 1 below) at screening/baseline. Acne vulgaris should be stable (for at least 3 months prior to screening), with minimal variation from day to day and within each day, in the opinion of the subject.
Table 1: Investigator's Global Assessment (IGA) Scale for Acne Vulgaris Grade Description 0 Clear skin with no inflammatory or non-inflammatory lesions 1 Almost clear; rare non-inflammatory lesions with no more than one small inflammatory lesion 2 Mild severity; greater than Grade 1; some non-inflammatory lesions with no more than a few inflammatory lesions (papules/pustules only, no nodular lesions) 3 Moderate severity; greater than Grade 2; up to many noninflammatory lesions and may have some inflammatory lesions, but no more than one small nodular lesion 4* Severe; greater than Grade 3; up to many non-inflammatory lesions and may have some inflammatory lesions, but no more than a few nodular lesions
* The eCRF will allow for reporting by Investigators of lesion worsening beyond Grade 4 with treatment. Acne vulgaris subjects with nodulocystic acne are not to be enrolled in the study.
Subjects who worsen beyond Grade 4 will be described in the safety evaluation. Note: Counts of nodules and cysts will be reported separately and not included in the inflammatory or non-inflammatory lesion counts.
Female subjects of (*WOCBP) must not be pregnant or lactating at the time of screening/baseline visit as documented by a negative urine pregnancy test with a sensitivity to at least 25 mIU/ml hCG .
*Female subjects of childbearing potential (WOCBP) are defined as sexually mature women without prior hysterectomy, or who have had any evidence of menses in the past 12 months.
However, women who have been amenorrheic for the past 12 or more months are still considered to be of childbearing potential, if the amenorrhea is possibly due to other causes, including prior chemotherapy, anti- estrogens, or ovarian suppression. women (defined as women who have been amenorrheic for at least 12 consecutive months, in the appropriate age group, without other known or suspected primary cause) or women who have been sterilized surgically or who are otherwise proven sterile (i.e., total hysterectomy, or bilateral oophorectomy with surgery at least 4 weeks prior to randomization) are not considered WOCBP. Subjects who have undergone tubal ligation are NOT considered as surgically sterile.
Female subjects of childbearing potential must be willing to use an acceptable form of during the study from the day of the first dose administration to 30 days after the last administration of study drug.
For the purposes of this study the following are considered acceptable methods of birth control: oral or injectable contraceptives, contraceptive patches, medroxyprogesterone acetate (ex. Depo-Provera®) with stabilized use for at least 3 months, vaginal contraceptive (ex. etonogestrel/ethinyl estradiol vaginal ring (ex. NuvaRing®), contraceptive implant with etonogestrel or equivalent, double barrier methods, (e.g.
condom and spermicide), intrauterine device (IUD), true abstinence (if in line with subject's lifestyle).
A sterile sexual partner is not considered an adequate form of birth control.
All male subjects must agree to use accepted methods of birth control with their partners, from the day of the first dose administration to 30 days after the last administration of study drug.
True abstinence is an acceptable method of birth control if in line with subject's lifestyle.
Female partners should use an acceptable method of birth control as described in the above criteria 7.
Exclusion Criteria:
Subjects who have used any of the following procedures on the face within 1 month prior to screening/baseline or use during the study:
Subjects who have used any of the following treatments within 1 month prior to screening/baseline or during the study:
Subjects who have used any of the following treatments within 2 weeks prior to screening/baseline or during the study:
Subject having symptoms* of Coronavirus Disease 2019 (COVID-19) within the 10 days prior to screening/baseline/visit 1 or have had close contact with someone with suspected or confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection within 10 days prior to screening/baseline/visit 1 or who are at high risk of SARS-CoV-2 infection, defined as adults whose locations or circumstances put them at appreciable risk of acquiring SARS-CoV-2 infections.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Trifarotene Cream, 0.005%, Apply to the affected areas of the face once daily for 84 days.
Drug: Trifarotene 0.005 % Topical Cream
AKLIEF® (Trifarotene Cream, 0.005%), Apply to the affected areas of the face once daily for 84 days.
Drug: AKLIEF®
Vehicle of the Test Product, Cream, Apply to the affected areas of the face once daily for 84 days.
Drug: Placebo
Cream
Cream
Also known as: Trifarotene 0.005 % Topical Cream
Cream
Also known as: Vehicle of Test Product
Primary Change in Inflammatory Lesion Counts
Mean percent change from screening/baseline to week 12 in the inflammatory (papules and pustules) lesion counts
Time frame: Baseline and 12 Weeks
Primary Change in Non-Inflammatory Lesion Count
Mean percent change from screening/baseline to week 12 in the noninflammatory (open and closed comedones) lesion counts.
Time frame: Baseline and 12 Weeks
| Milestone | Test: Trifarotene Cream, 0.005% | AKLIEF® | Vehicle Product |
|---|---|---|---|
| Started | 269 | 269 | 269 |
| Completed | 241 | 235 | 241 |
| Not completed | 28 | 34 | 28 |
| Withdrew: Lack of efficacy | 0 | 0 | 1 |
| Withdrew: Adverse event | 1 | 5 | 0 |
| Withdrew: Withdrawal by subject | 8 | 14 | 10 |
| Withdrew: Pregnancy | 0 | 0 | 1 |
| Withdrew: Protocol violation | 1 | 3 | 4 |
| Withdrew: Physician decision | 2 | 1 | 1 |
| Withdrew: Lost to follow-up | 16 | 11 | 11 |
Mean percent change from screening/baseline to week 12 in the inflammatory (papules and pustules) lesion counts
| Percent change | Test: Trifarotene Cream, 0.005% | AKLIEF® | Vehicle Product |
|---|---|---|---|
| Primary Change in Inflammatory Lesion Counts | -72.86 ± 33.364 | -78.83 ± 23.547 | -34.12 ± 38.332 |
Mean percent change from screening/baseline to week 12 in the noninflammatory (open and closed comedones) lesion counts.
| Percent change | Test: Trifarotene Cream, 0.005% | AKLIEF® | Vehicle Product |
|---|---|---|---|
| Primary Change in Non-Inflammatory Lesion Count | -62.03 ± 31.716 | -67.51 ± 27.577 | -27.30 ± 36.628 |
Collected over 7.5 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Test: Trifarotene Cream, 0.005% | 23/269 (8.6%) | 0/269 (0%) | 23/269 (8.6%) |
| AKLIEF® | 37/269 (13.8%) | 1/269 (0.4%) | 37/269 (13.8%) |
| Vehicle Product | 18/269 (6.7%) | 0/269 (0%) | 18/269 (6.7%) |
| Event | Test: Trifarotene Cream, 0.005% | AKLIEF® | Vehicle Product |
|---|---|---|---|
| Ovarian TorsionReproductive system and breast disorders | 0/269 | 1/269 | 0/269 |
| Event | Test: Trifarotene Cream, 0.005% | AKLIEF® | Vehicle Product |
|---|---|---|---|
| HeadacheNervous system disorders | 3/269 | 4/269 | 6/269 |
| Application site drynessGeneral disorders | 4/269 | 5/269 | 1/269 |
| NasopharyngitisGastrointestinal disorders | 4/269 | 5/269 | 3/269 |
| Application site erythemaGeneral disorders | 0/269 | 4/269 | 0/269 |
| Upper respiratory tract infectionInfections and infestations | 1/269 | 4/269 | 0/269 |
| DysmenorrhoeaReproductive system and breast disorders | 0/269 | 2/269 | 3/269 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/269 | 1/269 | 1/269 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 3/269 | 0/269 | 1/269 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 3/269 | 0/269 | 0/269 |
| Skin burning sensationSkin and subcutaneous tissue disorders | 2/269 | 3/269 | 0/269 |
| Age, Continuous(Years) | Test: Trifarotene Cream, 0.005% | AKLIEF® | Vehicle Product | Total |
|---|---|---|---|---|
| Mean | 23 ± 7.03 | 22.8 ± 7.31 | 23.5 ± 7.24 | 23.1 ± 7.19 |
| Sex: Female, Male(Participants) | Test: Trifarotene Cream, 0.005% | AKLIEF® | Vehicle Product | Total |
|---|---|---|---|---|
| Female | 98 | 127 | 95 | 320 |
| Male | 171 | 142 | 174 | 487 |
| Ethnicity (NIH/OMB)(Participants) | Test: Trifarotene Cream, 0.005% | AKLIEF® | Vehicle Product | Total |
|---|---|---|---|---|
| Hispanic or Latino | 172 | 182 | 181 | 535 |
| Not Hispanic or Latino | 97 | 87 | 88 | 272 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Test: Trifarotene Cream, 0.005% | AKLIEF® | Vehicle Product | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 2 | 1 | 0 | 3 |
| Asian | 20 | 18 | 16 | 54 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 42 | 45 | 45 | 132 |
| White | 193 | 196 | 196 | 585 |
| More than one race | 8 | 6 | 6 | 20 |
| Unknown or Not Reported | 4 | 3 | 6 | 13 |
| Baseline IGA Score(Participants) | Test: Trifarotene Cream, 0.005% | AKLIEF® | Vehicle Product | Total |
|---|---|---|---|---|
| 0=clear | 0 | 0 | 0 | 0 |
| 1=almost clear | 0 | 0 | 0 | 0 |
| 2=mild | 64 | 61 | 53 | 178 |
| 3=moderate | 184 | 186 | 185 | 555 |
| 4=severe | 21 | 22 | 31 | 74 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2022 to primary completion in May 2023, 7 months.
Results were first posted in Sep 2024, 1 year 4 months after primary completion.
Of 53 industry-sponsored phase 3 interventional studies under Acne Vulgaris, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 17. This study's 7 months is below that.
Counting every sponsor, half of 62 studies reached it within 13 months; a quarter within 10 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Trifarotene